Neurodevelopmental and Functional Outcomes: What Disease Modification Looks Like

For families living with Dravet syndrome, seizure frequency is only part of the burden. The continuous, daily reality is the developmental plateau, the communication deficits, the behavioral challenges, the gap that widens every year between their child and neurotypical peers. When families were asked what clinically meaningful improvement looked like to them, they identified gains of one to three points on the Vineland Adaptive Behavior Scales as significant. In the zorevunersen studies, some patients were achieving gains of seven points or more.

Dr. Wirrell walks through the neurodevelopmental findings. The studies used the same Vineland Adaptive Behavior Scales employed in the BUTTERFLY natural history study, allowing direct comparison. Across all subdomains of the Vineland, patients treated with zorevunersen showed incremental gains from year one to year two to year three -- a trajectory that looks fundamentally different from the natural history controls, where scores stagnated or declined. Communication emerged as a particularly significant domain, with meaningful improvements in both receptive and expressive language. She notes that families consistently identify communication as one of the most important functional goals for their children.

Dr. Schreiber expands on the multi-domain nature of the improvements. It is not one isolated area of function that changes -- it is multiple domains simultaneously, reflecting the broader impact of restoring NaV1.1 protein production. He points to the Global Impression of Change data as further validation: both clinicians and caregivers independently rated patients as minimally or much improved when comparing function before and after zorevunersen. A concrete example he offers is toilet training -- a child who achieves continence represents a meaningful shift in daily life and quality of life for the entire family, and the Vineland captures exactly these kinds of functional gains.

Dr. Wheless addresses what may have been a somewhat surprising finding: that gains were seen even in adolescents. Given that the nervous system is thought to be less plastic as children age, and that the natural history of Dravet already involves years of developmental stagnation, there was a question of whether older patients would benefit from neurodevelopmental improvements at all. The data suggest they do. While numbers in the adolescent subgroup are small and further study will be needed, the absence of an age-related ceiling on functional response through the 2 to 18 year range studied is meaningful and has important implications for how the field thinks about treatment eligibility. As Dr. Wheless puts it: the disease has been progressive, so not losing ground is itself meaningful, but gaining ground -- at any age -- is a different and better outcome entirely.

In the final episode, the panelists discuss the safety and tolerability profile of zorevunersen, including what makes its adverse event landscape distinctive compared to standard antiseizure medications and why the very low rate of treatment discontinuation speaks to the overall tolerability of this approach.